Helicobacter pylori

Häftad, Engelska, 2018

1 861 kr

Beställningsvara. Skickas inom 11-20 vardagar. Fri frakt över 249 kr.

Beskrivning

This book presents thecurrent state of knowledge regarding the ability of Helicobacter pylori to colonize the gastrointestinal tract, theglobal epidemiology of H. pylori-related gastroduodenal and other diseases, diagnosis andtreatment methods, guidelines for eradication, antibiotic resistance, thereinfection rate after H.

Produktinformation

Utgivningsdatum:2018-12-09
Mått:178 x 254 x 29 mm
Vikt:1 182 g
Format:Häftad
Språk:Engelska
Antal sidor:556
Förlag:Springer Verlag, Singapore
ISBN:9789811357060

Utforska kategorier

Mer om författaren

Nayoung Kim MD Ph.D., Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Republic of Korea

Innehållsförteckning

Part 1. Epidemiology-Prevalence andTransmission routes of H. pylori.- Part 2. Pathophysiology.- 1) Colonization ofH. pylori in the stomach.- 2) Brief description of Pathophysiology.- 3) Immunemechanism.- 4) Change of acid secretion, ghrelin and leptin by H. pylori.- 5) H.pylori virulence factors.- A: toxin (CagA, VacA, DupA, OipA, IceA).- B: geneticpolymorphism of toxin and disease.- 6) Host factors: genetic polymorphism,etc.- Part 3. Diagnosis.- 1) Serology.- 2) Histology.- 3) Culture.- 4) UBT.- 5)Stool antigen.- 6) Specific conditions.- A: Children.- B: Bleeding.- Part4. Symptom.- 1)Symptom of acute and chronic H. pylori infection.- Part 5.Disease.- 1) Atrophic gastritis and Intestinal metaplasia.- 2) Functional dyspepsia.-3) Peptic ulcer.- 4) MALToma.- 5) Gastric cancer.- A: Synopsis and Epidemiologyof gastric cancer.- B1: Pathogenesis: i.Genetic alternation (mutations intumor-related genes) induced by Activation-induced cytidine deaminase (AID).- B2:Pathogenesis: ii. Epigenetic mechanisms: aberrant DNA methylation, microRNA.- B3:Pathogenesis:iii. Macrophage inhibitory factor (MIF).- B4: Pathogenesis: iv.Epidermal mesenchyme transition (EMT).- B5: Pathogenesis: v. ABO blood type.- B6:Pathogenesis: vi. First relatives of gastric cancer.- C: H. pylori-negativegastric cancer.- 6) Gastroesophageal reflux disease (GERD).- 7) NSAID-inducedgastropathy and H. pylori infection.- 8) Extraintestinal manifestations of H.pylori infection.- A: Iron deficiency anemia.- B: Idiopathic thrombocytopenicpurpura.- C: Heart disease.- D: Atopy and allergy.- Part 6. Antibioticresistance.- 1) Synopsis of antibiotic resistance.- 2) Clarithromycin.- 3)Amoxicillin.- 4) Quinolone.- 5) Metronidazole.- Part 7. Treatment.- 1) Synopsisof antibiotic treatment.- 2) Triple therapy.- 3) Quadruple therapy.- 4)Sequential therapy.- 5) Concomitant therapy.- 6) Tailored therapy based onantibiotic resistance.- 7) Levofloxacin or rifabutin based triple therapy.- 8)Probiotics.- 9) Treatment guidelines.- 10) Screening method of early gastriccancer.- 11) Recrudescence and reinfection.- Part 8. Consequences of H.pylori eradication.- 1) Peptic ulcer disease.- 2) atrophic gastritis andIntestinal metaplasia.- 3) Gastric cancer.- Part 9. The effect of H. pylori onthe other microbiota of stomach.- The effect of H. pylori on the othermicrobiota of stomach.- Part 10. Animal model- H. pylori, H. felis.